ATE516270T1 - Neue derivate von psammaplin a, verfahren zu ihrer synthese und ihre verwendung für die vorbeugung oder behandlung von krebs - Google Patents
Neue derivate von psammaplin a, verfahren zu ihrer synthese und ihre verwendung für die vorbeugung oder behandlung von krebsInfo
- Publication number
- ATE516270T1 ATE516270T1 AT08763019T AT08763019T ATE516270T1 AT E516270 T1 ATE516270 T1 AT E516270T1 AT 08763019 T AT08763019 T AT 08763019T AT 08763019 T AT08763019 T AT 08763019T AT E516270 T1 ATE516270 T1 AT E516270T1
- Authority
- AT
- Austria
- Prior art keywords
- psammaplin
- cancer
- synthesis
- prevention
- treatment
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 230000015572 biosynthetic process Effects 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 238000003786 synthesis reaction Methods 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title 1
- 229930184000 psammaplin Natural products 0.000 title 1
- LMAFSGDNHVBIHU-XUIWWLCJSA-N (2e)-3-(3-bromo-4-hydroxyphenyl)-n-[2-[2-[[(2e)-3-(3-bromo-4-hydroxyphenyl)-2-hydroxyiminopropanoyl]amino]ethyldisulfanyl]ethyl]-2-hydroxyiminopropanamide Chemical class C=1C=C(O)C(Br)=CC=1C/C(=N\O)C(=O)NCCSSCCNC(=O)C(=N/O)/CC1=CC=C(O)C(Br)=C1 LMAFSGDNHVBIHU-XUIWWLCJSA-N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07290253A EP1964835A1 (de) | 2007-02-28 | 2007-02-28 | Derivate von Psammaplin A, Verfahren zu ihrer Synthese und ihre Verwendung für die Vorbeugung oder Behandlung von Krebs |
| PCT/IB2008/001887 WO2008125988A1 (en) | 2007-02-28 | 2008-02-28 | Novel derivatives of psammaplin a, a method for their synthesis and their use for the prevention or treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE516270T1 true ATE516270T1 (de) | 2011-07-15 |
Family
ID=37998389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT08763019T ATE516270T1 (de) | 2007-02-28 | 2008-02-28 | Neue derivate von psammaplin a, verfahren zu ihrer synthese und ihre verwendung für die vorbeugung oder behandlung von krebs |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8338473B2 (de) |
| EP (2) | EP1964835A1 (de) |
| JP (1) | JP5329439B2 (de) |
| CN (1) | CN101720315B (de) |
| AT (1) | ATE516270T1 (de) |
| AU (1) | AU2008238924B2 (de) |
| CA (1) | CA2678833A1 (de) |
| ES (1) | ES2372717T3 (de) |
| IL (1) | IL200410A (de) |
| WO (1) | WO2008125988A1 (de) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9238069B2 (en) | 2009-12-16 | 2016-01-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method of sensitizing cancer cells to the cytotoxic effects of death receptor ligands in cancer treatment |
| CN102503869B (zh) * | 2011-10-19 | 2014-05-21 | 沈阳药科大学 | 2-羟亚胺苯丙酰胺基乙二硫基类衍生物及其应用 |
| EP2730558A1 (de) * | 2012-11-08 | 2014-05-14 | Ikerchem, S.L. | Indolderivate, pharmazeutische Zusammensetzungen mit solchen Indolen und deren Verwendung als DNA-Methylierungsmodulatoren |
| EP3207932A1 (de) | 2016-02-19 | 2017-08-23 | Universität Stuttgart | Dna-methyltransferaseninhibitoren für rett-syndromtherapie |
| EP3503896A1 (de) * | 2016-08-26 | 2019-07-03 | Idogen AB | Psammaplin a zur modulation der ido-expression |
| CN107739316B (zh) * | 2017-11-14 | 2020-07-14 | 中国医科大学 | 一种溴代酪氨酸生物碱类化合物及其制备方法和用途 |
| CN111548286B (zh) * | 2020-05-13 | 2022-09-06 | 沈阳药科大学 | 一种具有hdac3抑制活性的psa衍生物及其应用 |
| CN114890932A (zh) * | 2022-06-24 | 2022-08-12 | 大理大学 | 一种吲哚生物碱Luteoride A的首次全合成工艺 |
| CN115028567A (zh) * | 2022-06-24 | 2022-09-09 | 大理大学 | 一种吲哚生物碱Luteoride B的合成工艺 |
| CN115925675B (zh) * | 2022-11-10 | 2025-04-01 | 中国海洋大学 | 一种Psammaplin A类衍生物及其制备方法和应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0624569T3 (da) * | 1991-02-28 | 1998-10-26 | Merrell Pharma Inc | MMDA-antagonister |
| JPH0725858A (ja) * | 1993-07-13 | 1995-01-27 | Otsuka Pharmaceut Co Ltd | ピペラジン誘導体 |
| DE19814838C2 (de) * | 1998-04-02 | 2001-01-18 | Asta Medica Ag | Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung |
| CA2618770A1 (en) * | 2005-08-25 | 2007-03-01 | Emory University | Hif inhibitors |
-
2007
- 2007-02-28 EP EP07290253A patent/EP1964835A1/de not_active Withdrawn
-
2008
- 2008-02-28 WO PCT/IB2008/001887 patent/WO2008125988A1/en not_active Ceased
- 2008-02-28 CA CA002678833A patent/CA2678833A1/en not_active Abandoned
- 2008-02-28 EP EP08763019A patent/EP2137147B1/de not_active Not-in-force
- 2008-02-28 AT AT08763019T patent/ATE516270T1/de not_active IP Right Cessation
- 2008-02-28 US US12/528,020 patent/US8338473B2/en not_active Expired - Fee Related
- 2008-02-28 CN CN2008800061525A patent/CN101720315B/zh not_active Expired - Fee Related
- 2008-02-28 ES ES08763019T patent/ES2372717T3/es active Active
- 2008-02-28 AU AU2008238924A patent/AU2008238924B2/en not_active Ceased
- 2008-02-28 JP JP2009551288A patent/JP5329439B2/ja not_active Expired - Fee Related
-
2009
- 2009-08-13 IL IL200410A patent/IL200410A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| IL200410A0 (en) | 2010-05-31 |
| AU2008238924A1 (en) | 2008-10-23 |
| US20100120885A1 (en) | 2010-05-13 |
| CA2678833A1 (en) | 2008-10-23 |
| EP2137147B1 (de) | 2011-07-13 |
| JP5329439B2 (ja) | 2013-10-30 |
| EP2137147A1 (de) | 2009-12-30 |
| AU2008238924B2 (en) | 2013-06-27 |
| WO2008125988A1 (en) | 2008-10-23 |
| IL200410A (en) | 2013-10-31 |
| US8338473B2 (en) | 2012-12-25 |
| EP1964835A1 (de) | 2008-09-03 |
| ES2372717T3 (es) | 2012-01-25 |
| JP2010520192A (ja) | 2010-06-10 |
| CN101720315B (zh) | 2012-07-18 |
| CN101720315A (zh) | 2010-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0409198A (pt) | derivados quinolin-2-ona para o tratamento de doenças de vias aéreas | |
| DK1853602T3 (da) | Kemiske forbindelser | |
| CY1108275T1 (el) | Χημικες ενωσεις | |
| NO20091661L (no) | Anvendelse av pegylert IL-10 for a behandle kreft | |
| TW200716606A (en) | Chemical compounds | |
| TW200800963A (en) | Chemical compounds | |
| IL200410A0 (en) | Novel derivatives of psammaplin a, a method for their synthesis and their use for the prevention or treatment of cancer | |
| UA104137C2 (ru) | Пиридилсодержащие ингибиторы передачи сигнала через белок hedgehog | |
| EA200700851A1 (ru) | Получение и применение бифенил-4-илкарбониламинокислотных производных для лечения ожирения | |
| MX361467B (es) | Compuestos de isoindolina para uso en el tratamiento de cancer. | |
| GEP20084360B (en) | Substituted quinoline compounds | |
| BRPI0908635A8 (pt) | composto, composição farmacêutica e método de tratamento de câncer | |
| WO2007109279A3 (en) | Tetrahydropyridothienopyrimidine compounds and methods of use thereof | |
| ATE556074T1 (de) | Neue imidazoä1,5-aüpyridinderivate, verfahren zu deren herstellung und pharmazeutische zusammensetzungen, die diese enthalten | |
| MA32943B1 (fr) | Piperidine spiro pyrrolidione et piperidinone substituees, leur preparation et leur utilisation therapeutique | |
| MX2010003269A (es) | Derivados de pirrolotriazina utiles para tratar cancer a traves de la inhibicion de la aurora quinasa. | |
| WO2010075280A3 (en) | Coumarin-based compounds for the treatment of alzheimer's disease and cancer | |
| ATE521609T1 (de) | Aminothiazolylpyrimidinderivate und ihre verwendung bei der behandlung von krebs | |
| MX2009013205A (es) | Derivados de pirazoloquinolina urea terapeuticos. | |
| MX2010000956A (es) | Derivados de isoftalamida que inhiben actividad de beta-secretasa. | |
| MX2009013197A (es) | Derivados terapeuticos de pirazolonaftiridina. | |
| NO20091495L (no) | Pyrazolopyrimidinderivat | |
| NZ597857A (en) | Method and composition for treating mucosal disorders | |
| WO2010072770A3 (en) | Griseofulvin analogues for the treatment of cancer by inhibition of centrosomal clustering | |
| CY1110027T1 (el) | Συνδυασμος ενωσεων πυριμιδυλαμινοβενζαμιδης και ιματινιβης για τη θεραπεια ή την προληψη των νεοπλασματικων ασθενειων |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |